Tags

Type your tag names separated by a space and hit enter

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Trends Pharmacol Sci. 2020 08; 41(8):531-543.TP

Abstract

Recent advances in the pathophysiologic understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc. Therefore, the treatment of cytokine storm has been proposed as a critical part of rescuing severe COVID-19. Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clinical outcomes in COVID-19. Below, we review the possibilities and challenges of targeting the pathway in COVID-19.

Authors+Show Affiliations

Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University; Shanxi Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Taiyuan, 030032, China; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University; Shanxi Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Taiyuan, 030032, China; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: wt7636@126.com.Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University; Shanxi Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Taiyuan, 030032, China; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Electronic address: dy0711@gmail.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32580895

Citation

Luo, Wei, et al. "Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19." Trends in Pharmacological Sciences, vol. 41, no. 8, 2020, pp. 531-543.
Luo W, Li YX, Jiang LJ, et al. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends Pharmacol Sci. 2020;41(8):531-543.
Luo, W., Li, Y. X., Jiang, L. J., Chen, Q., Wang, T., & Ye, D. W. (2020). Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends in Pharmacological Sciences, 41(8), 531-543. https://doi.org/10.1016/j.tips.2020.06.007
Luo W, et al. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends Pharmacol Sci. 2020;41(8):531-543. PubMed PMID: 32580895.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. AU - Luo,Wei, AU - Li,Yi-Xin, AU - Jiang,Li-Jun, AU - Chen,Qian, AU - Wang,Tao, AU - Ye,Da-Wei, Y1 - 2020/06/17/ PY - 2020/05/19/received PY - 2020/06/11/revised PY - 2020/06/12/accepted PY - 2020/6/26/pubmed PY - 2020/7/29/medline PY - 2020/6/26/entrez KW - COVID-19 KW - JAK inhibitors KW - cytokine release syndrome SP - 531 EP - 543 JF - Trends in pharmacological sciences JO - Trends Pharmacol Sci VL - 41 IS - 8 N2 - Recent advances in the pathophysiologic understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc. Therefore, the treatment of cytokine storm has been proposed as a critical part of rescuing severe COVID-19. Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clinical outcomes in COVID-19. Below, we review the possibilities and challenges of targeting the pathway in COVID-19. SN - 1873-3735 UR - https://www.unboundmedicine.com/medline/citation/32580895/Targeting_JAK_STAT_Signaling_to_Control_Cytokine_Release_Syndrome_in_COVID_19_ DB - PRIME DP - Unbound Medicine ER -